retatrutide ada 2025 results Provides Substantial Weight Loss in Patients With Obesity or Overweight LLY's Retatrutide Nears 2027 Filing

Three things

Who Profits: Eli Lilly (LLY) FY2025 Revenue: $63.5B | GLP-1 Revenue (Mounjaro + Zepbound): $35-38B (estimated) | Operating Margin: 31% | CEO (David Ricks): $24.3M This issue's mechanism: Eli Lilly is winning the market share battle against Novo

Lean mass supports resting metabolic rate, physical function, and long-term weight maintenance

Some patients may experience mild redness or slight tenderness in the treated areas, but these effects typically resolve within a few hours

The SURPASS-1 trial demonstrated significant improvements in glycemic control and substantial reductions in body weight with all three doses of tirzepatide (5 mg, 10 mg, or 15 mg) compared to placebo over a 40-week period

Clinical trial dosing protocol Phase 2 and Phase 3 trials used a titration approach, starting at lower doses and increasing gradually to minimize gastrointestinal side effects